Similar to the data with genetic deletion of C3aR, the use of C3aR antagonist did not affect the anti-cBSA IgG concentrations (Figure 4A), but it almost entirely prevented the glomerular disease, as documented by the low albuminuria levels (Figure 4B). The gene discussed is C3AR1; the disease is glomerular disorder.